Ciprofloxacin - GlaxoSmithKline

Drug Profile

Ciprofloxacin - GlaxoSmithKline

Alternative Names: GR 37547

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bacterial infections

Most Recent Events

  • 28 Aug 2017 GlaxoSmithKline completes a phase I trial in Bacterial infections (In volunteers) in South Africa (PO) (NCT03150082)
  • 01 Aug 2017 Phase-I clinical trials in Bacterial infections (In volunteers) in South Africa (PO) (NCT03150082)
  • 10 May 2017 GlaxoSmithKline plans a phase I trial for Bacterial infections (In volunteers) (NCT03150082)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top